Home
/
Issue 1
/
Research & Development
/
Using diseases to find cures

The Magazine

Issue 1

This is a short description of the magazine.

- Issue 19
  Jun 2010
- Issue 18
  Feb 2010
- Issue 17
  Sep 2009
- Issue 16
  Jun 2009
- Issue 15
  Feb 2009
- Issue 14
  Oct 2008
- Issue 13
  Jul 2008
- Issue 12
  Mar 2008
- Issue 11
  Dec 2007
- Issue 10
  Oct 2007
- Issue 9
  Jul 2007
- Issue 8
  Apr 2007
- Issue 7
  Jan 2007
- Issue 6
  Dec 2006
- Issue 5
  Oct 2006
- Issue 4
  Mar 2006
- Issue 3
  Mar 2006
- Issue 2
  Mar 2006
- Issue 1
  Mar 2006

Blog

Spencer Green
Chairman, GDS International

Sales and the 'Talent Magnet'

A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?
26 May 2011

White Papers

View all White Papers

Using diseases to find cures

ORIDIS Biomed | www.oridis-biomed.com

No Comments

Prof. Dr. Kurt Zatloukal, Founder and CEO of Oridis Biomed, speaks to NGP Editor Alice Sharp.

Questions include:
I understand that big pharma companies have so far not really focused on systematic investigation of diseased tissues to support their drug development programs? Why do you think this is?

More like this...

A new approach to outsourced pharmaceutical man...

Pharmaceutical companies face a myriad of challenges day in and day out.
Read more
Wired science

This article looks at how electronic lab notebooks boost research productivity while ensuring legally valid record keeping for IP creation.
Read more
Ship of dreams

The National Human Genome Research Institute (NHGRI) was established in 1989 with the primary mission to lead the National Institutes of Health (NIH) contribution to the Human...
Read more
On side

Why ACRO is supporting and assisting the Critical Path initiative.
Read more
Case study: The right chemistry

On 20 October, Charles River Laboratories International, Inc. and Inveresk Research Group, Inc. officially merged under the Charles River Laboratories name
Read more
Shaping third party production

Just as in the automobile, electronics and aerospace industries, third party or sub-contracted manufacturing has become an essential strategy for pharmaceutical laboratories.
Read more

View all similar articles

Disclaimer: All comments posted in a personal capacity

In order to post a comment you need to be regsitered and signed in.
Register | Sign in

No Comments Have Been Submitted

Disclaimer: All comments posted in a personal capacity

Source: www.ngpharma.com
© 2012 GDS Publishing Ltd. All rights reserved.